Cantillon Capital Management LLC Lowers Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Cantillon Capital Management LLC lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 866,770 shares of the medical research company’s stock after selling 9,495 shares during the quarter. Thermo Fisher Scientific comprises approximately 2.3% of Cantillon Capital Management LLC’s portfolio, making the stock its 22nd biggest position. Cantillon Capital Management LLC owned about 0.23% of Thermo Fisher Scientific worth $420,401,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Hudson Value Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 14.6% in the third quarter. Hudson Value Partners LLC now owns 10,614 shares of the medical research company’s stock valued at $5,148,000 after acquiring an additional 1,356 shares in the last quarter. UNIVEST FINANCIAL Corp lifted its position in Thermo Fisher Scientific by 12.9% in the third quarter. UNIVEST FINANCIAL Corp now owns 35,515 shares of the medical research company’s stock valued at $17,226,000 after purchasing an additional 4,071 shares during the period. Coign Capital Advisors LLC boosted its holdings in Thermo Fisher Scientific by 9.9% in the 3rd quarter. Coign Capital Advisors LLC now owns 1,362 shares of the medical research company’s stock valued at $660,000 after purchasing an additional 123 shares in the last quarter. Parkside Financial Bank & Trust increased its position in Thermo Fisher Scientific by 31.9% during the 3rd quarter. Parkside Financial Bank & Trust now owns 1,290 shares of the medical research company’s stock worth $626,000 after purchasing an additional 312 shares during the period. Finally, Facet Wealth Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at approximately $233,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Up 0.4%

Shares of TMO opened at $639.03 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99. The stock has a market cap of $240.09 billion, a price-to-earnings ratio of 36.92, a price-to-earnings-growth ratio of 4.19 and a beta of 0.91. The firm has a 50 day simple moving average of $589.96 and a 200-day simple moving average of $529.43.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the prior year, the firm earned $5.28 EPS. Thermo Fisher Scientific’s quarterly revenue was up 4.9% on a year-over-year basis. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a stock buyback program on Thursday, November 6th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 15th. Investors of record on Monday, December 15th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date was Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 10,725 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the sale, the executive vice president directly owned 18,731 shares of the company’s stock, valued at $11,238,600. This trade represents a 36.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 7,250 shares of the business’s stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $566.10, for a total transaction of $4,104,225.00. Following the completion of the transaction, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $64,400,668.20. This represents a 5.99% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 131,767 shares of company stock worth $76,467,793 in the last 90 days. 0.33% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. Leerink Partners increased their price target on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. TD Cowen reissued a “buy” rating on shares of Thermo Fisher Scientific in a report on Wednesday, January 7th. Wells Fargo & Company increased their target price on shares of Thermo Fisher Scientific from $635.00 to $675.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, The Goldman Sachs Group assumed coverage on Thermo Fisher Scientific in a report on Tuesday, December 9th. They issued a “buy” rating and a $685.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $625.47.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.